Australian court affirms Mylan patent invalidation
06-07-2020
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
English court gives Mylan green-light to sell generic insomnia drug
04-06-2020
ricochet64 / Shutterstock.com
The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
English Court of Appeal, Mylan, Neurim, generic, injunction, insomnia, patent infringement, Circadin
